fda warning letter hims & hers compounded semaglutide september 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of U.S. FDA sends drug advertising

The recommended starting dose based on clinical trial protocols is 2mg once weekly

Malpractice insurance: Notify your malpractice carrier that you are adding obesity medicine and weight management services

Under the if-all-adhere estimand, CagriSema produced 23.0% weight loss at 84 weeks, against 25.5% for tirzepatide

So much for the easy fix heres what often comes with it: Physical setbacks like nausea, bloating, fatigue, and digestive discomfort quietly test the bodys tolerance

Further genetic analysis identified 16 of them with biallelic heterozygous/homozygous mutations and 10 newborns with one mutation in SLC22A5